|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
|
AU2000240570A1
(en)
|
2000-03-29 |
2001-10-08 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
|
AU9598601A
(en)
|
2000-10-20 |
2002-04-29 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
|
TWI263640B
(en)
|
2001-12-19 |
2006-10-11 |
Bristol Myers Squibb Co |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1684762A4
(en)
|
2003-11-13 |
2009-06-17 |
Ambit Biosciences Corp |
UREA DERIVATIVES AS MODULATORS OF KINASE
|
|
MX2007011041A
(es)
|
2005-03-10 |
2008-02-22 |
Cgi Pharmaceuticals Inc |
Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
|
|
US20100249030A1
(en)
|
2007-07-31 |
2010-09-30 |
Schering Corporation |
Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
|
|
EP3147281A1
(en)
|
2008-03-17 |
2017-03-29 |
Ambit Biosciences Corporation |
Quinazoline derivatives as raf kinase modulators and methods of use thereof
|
|
CA2737639A1
(en)
|
2008-09-25 |
2010-04-01 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
TW201018682A
(en)
|
2008-09-25 |
2010-05-16 |
Kyorin Seiyaku Kk |
Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
|
|
MX2012001974A
(es)
|
2009-08-19 |
2012-04-11 |
Ambit Biosciences Corp |
Compuestos de biarilo y metodos de uso de los mismos.
|
|
JP2013525308A
(ja)
|
2010-04-16 |
2013-06-20 |
キュリス，インコーポレイテッド |
Ｋ−ｒａｓ変異を有する癌の治療
|
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
EP2802212B1
(en)
|
2012-01-12 |
2015-12-30 |
Basf Se |
Herbicidal isoxazolo[5,4-b]pyridines
|
|
EP2997030B1
(en)
|
2013-05-14 |
2017-08-09 |
Nerviano Medical Sciences S.R.L. |
Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
|
|
CA2914815A1
(en)
|
2013-06-11 |
2014-12-18 |
Kala Pharmaceuticals, Inc. |
Urea derivatives and uses thereof
|
|
EA029412B1
(ru)
|
2013-06-28 |
2018-03-30 |
Бейджин, Лтд. |
Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
|
|
US9290519B2
(en)
|
2013-11-15 |
2016-03-22 |
Exxonmobil Chemical Patents Inc. |
Pyridyldiamido transition metal complexes, production and use thereof
|
|
KR102562866B1
(ko)
|
2014-11-14 |
2023-08-04 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
|
|
US10688077B2
(en)
|
2015-02-26 |
2020-06-23 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inflammasome activation in myelodysplastic syndromes
|
|
US10259816B2
(en)
|
2015-04-24 |
2019-04-16 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd. |
Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
|
|
RU2724345C2
(ru)
|
2015-10-09 |
2020-06-23 |
Галапагос Нв |
N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
|
|
JP6910359B2
(ja)
|
2016-01-22 |
2021-07-28 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体
|
|
CN107176951A
(zh)
|
2016-03-11 |
2017-09-19 |
恩瑞生物医药科技（上海）有限公司 |
一种脲类化合物、其制备方法及其医药用途
|
|
US10167703B2
(en)
|
2016-03-31 |
2019-01-01 |
Saudi Arabian Oil Company |
Optimal well placement under constraints
|
|
JP6867417B2
(ja)
|
2016-06-21 |
2021-04-28 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体
|
|
US20190241573A1
(en)
|
2016-07-20 |
2019-08-08 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
EP3296297A1
(en)
|
2016-09-15 |
2018-03-21 |
Centre National De La Recherche Scientifique |
Benzimidazol derivatives for treating filovirus infection
|
|
AU2018272986A1
(en)
|
2017-05-26 |
2019-12-12 |
Ichnos Sciences SA |
Novel inhibitors of MAP4K1
|
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
KR20200087759A
(ko)
|
2017-11-09 |
2020-07-21 |
인플라좀 리미티드 |
신규한 설폰아마이드 카복스아마이드 화합물
|
|
CA3093469A1
(en)
|
2018-03-09 |
2019-09-12 |
The Brigham And Women's Hospital, Inc. |
Combination therapy for cardiovascular diseases
|
|
IL277408B2
(en)
|
2018-04-05 |
2024-08-01 |
Merck Patent Gmbh |
Heteroaryl compounds as IRAK type II inhibitors and their use
|
|
CN112654350A
(zh)
|
2018-07-03 |
2021-04-13 |
诺华股份有限公司 |
使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
|
|
WO2020035495A1
(en)
|
2018-08-14 |
2020-02-20 |
Cynora Gmbh |
Organic molecules for optoelectronic devices
|
|
JP2021536458A
(ja)
|
2018-09-04 |
2021-12-27 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
アリール炭化水素レセプター・アンタゴニスト及び使用方法
|
|
GB201815045D0
(en)
|
2018-09-14 |
2018-10-31 |
Univ Ulster |
Bispecific antibody targeting IL-1R1 and NLPR3
|
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
CN113226309B
(zh)
|
2018-12-03 |
2024-10-29 |
珠海岐微生物科技有限公司 |
一种治疗年龄相关性黄斑变性的方法
|
|
WO2020139748A1
(en)
|
2018-12-28 |
2020-07-02 |
Cedars-Sinai Medical Center |
Methods of treating inflammatory bowel diseases that target ripk2
|
|
EP3908274A1
(en)
|
2019-01-11 |
2021-11-17 |
Universitätsspital Basel |
Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
|
|
EP3917907B1
(en)
|
2019-01-29 |
2025-05-21 |
Universitá Degli Studi Di Salerno |
Modulators of potassium ion channels and uses thereof
|
|
CN111646995B
(zh)
|
2019-03-04 |
2023-03-21 |
四川大学 |
4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
US11559536B2
(en)
|
2019-05-20 |
2023-01-24 |
Duke University |
Compositions and methods for the treatment of inflammation in urological pathology
|
|
CA3152508A1
(en)
|
2019-08-29 |
2021-03-04 |
Hibercell, Inc. |
Perk inhibiting pyrrolopyrimidine compounds
|
|
WO2021057877A1
(zh)
*
|
2019-09-26 |
2021-04-01 |
深圳市塔吉瑞生物医药有限公司 |
取代的芳香稠合环衍生物及其组合物及用途
|
|
US20230140941A1
(en)
|
2020-03-13 |
2023-05-11 |
University Of Maryland, Baltimore |
Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
|
|
AU2020436612A1
(en)
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
|
US20230172941A1
(en)
|
2020-03-20 |
2023-06-08 |
The Johns Hopkins University |
Prophylaxis and treatment of pathogenic coronavirus infections
|
|
RS65962B1
(sr)
*
|
2020-05-08 |
2024-10-31 |
Halia Therapeutics Inc |
Inhibitori nek7 kinaze
|
|
WO2021226547A2
(en)
|
2020-05-08 |
2021-11-11 |
Halia Therapeutics, Inc. |
Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
|
|
US20230257367A1
(en)
|
2020-06-02 |
2023-08-17 |
Chengdu Kanghong Pharmaceutical Co., Ltd. |
Novel thyroid hormone beta receptor agonist
|
|
EP4161933A1
(en)
|
2020-06-08 |
2023-04-12 |
Halia Therapeutics, Inc. |
Inhibitors of nek7 kinase
|
|
GB202010464D0
(en)
|
2020-07-08 |
2020-08-19 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
|
|
EP4232020A4
(en)
|
2020-10-21 |
2024-08-07 |
Kura Oncology, Inc. |
Treatment of hematological malignancies with inhibitors of menin
|
|
US20240400551A1
(en)
|
2021-01-25 |
2024-12-05 |
Halia Therapeutics, Inc. |
Nek7 inhibitors
|
|
WO2022192944A1
(en)
|
2021-03-15 |
2022-09-22 |
Genieus Genomics Pty Ltd |
Combination therapy for treatment of als
|
|
WO2022216680A1
(en)
|
2021-04-05 |
2022-10-13 |
Halia Therapeutics, Inc. |
Nek7 inhibitors
|
|
WO2022226349A1
(en)
|
2021-04-22 |
2022-10-27 |
Essa Pharma, Inc. |
Androgen receptor modulators and methods for their use
|
|
US20240336563A1
(en)
|
2021-04-26 |
2024-10-10 |
The Regents Of The University Of California |
G-alpha-s inhibitors and uses thereof
|
|
US20240287081A1
(en)
|
2021-06-09 |
2024-08-29 |
Icahn School Of Medicine At Mount Sinai |
Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
|
|
CN115616216B
(zh)
|
2021-07-15 |
2025-08-12 |
华南理工大学 |
抑制或阻断faah与nlrp3之间相互作用的制剂的用途
|
|
IL309085A
(en)
|
2021-07-23 |
2024-02-01 |
Novartis Ag |
Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis
|
|
TW202333693A
(zh)
|
2021-12-31 |
2023-09-01 |
大陸商上海翰森生物醫藥科技有限公司 |
苯并哌啶衍生物調節劑、其製備方法和應用
|